Journal of Clinical and Translational Hepatology

Journal of Clinical and Translational Hepatology

Saturday, 10 / 24 / 2020

Articles

LETTER TO THE EDITOR

Revised Nomenclature for Fatty Liver Disease: Cutting through the Confusion

Khalid Alsawat1, Almoutaz Hashim2, Mohamed Alboraie3 and Yasser Fouad*,4 

1  Liver Research Center, Department of Medicine, College of Medicine, King Saud University, Riyadh, Kingdom of Saudi Arabia
2  Department of Medicine, University of Jeddah, Jeddah, Kingdom of Saudi Arabia
3  Department of Internal Medicine, Al-Azhar University, Cairo, Egypt
4  Department of Gastroenterology and Endemic Medicine, Minia University, Minia, Egypt
*Correspondence to: Yasser Fouad, Gastroenterology and Hepatology, Endemic Medicine Department, Minia University, Main Road, Minia 11432, Egypt. Tel: +201091318555, E-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

Journal of Clinical and Translational Hepatology 2020;8(3):354-355 DOI: 10.14218/JCTH.2020.00049
Received: May 28, 2020 Accepted: August 27, 2020 Published online: September 21, 2020

Abstract

Numerous clinically relevant drug-drug interactions (DDIs) were identified with the newer generation DAAs and commonly prescribed drugs. NS3/4A protease inhibitors are more likely to be involved in DDIs, followed by NS5A inhibitors and NS5B polymerase inhibitor. The majority of clinically relevant DDIs are predictable, according to known pharmacokinetic, pharmacodynamics, and physicochemical properties of DAAs; however, in select cases, unpredictable DDIs do occur. As expected, many drug interactions exist between newer generation DAAs and commonly prescribed medications. While the majority of clinically relevant interactions are predictable, many require therapeutic dose adjustment or careful selection of non-interacting drugs. In select cases, severe and unpredictable drug interactions can occur. Clinicians should consult hepatitis C virus pharmacotherapy experts and tertiary drug interaction resources when initiating DAA therapy in patients taking other medications.Nomenclature of disease is pivotal for both clinicians and patients, as well as for other stakeholders, and serves as a critical nosological reference point. The term ‘non-alcoholic fatty liver disease (NAFLD)’ was introduced to a broader audience by Ludwig and colleagues in 1980.1 The authors coined this term, trying to describe a clinical entity from fatty liver disease that is not caused by increased alcohol intake. In their description and subsequent guidelines, it was pointed out that diagnosis is based on the exclusion of significant alcohol intake and other liver diseases.

Journal of Clinical and Translational Hepatology 2020 vol. 8, 354-355  [ Html  ] [ PDF Full-text ]

© The Authors 2020. This article is published under the terms of the Creative Commons Attribution-Noncommercial License (CC BY-NC 4.0), which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

 logo

You are here: Home